Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment

Autoimmunity Reviews

Volumn 11, Issue 8, 2012, Pages 572-576

  Bijl, M ^a   Agmon Levin, N ^b   Dayer, J M ^c,d   Israeli, E ^a   Gatto, M ^d   Shoenfeld, Y ^b,e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b The Zabludowicz Center for Autoimmune Diseases Sheba Medical Center   (Israel)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF PADOVA   (Italy)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune diseases; Rheumatic diseases; Vaccination

Indexed keywords

BCG VACCINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; RITUXIMAB; VARICELLA ZOSTER VACCINE;

AUTOIMMUNE DISEASE; AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; BCG VACCINATION; CHRONIC ARTHRITIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PNEUMOCOCCAL VACCINATION; PRACTICE GUIDELINE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STREPTOCOCCUS PNEUMONIA; THROMBOCYTOPENIC PURPURA; VACCINATION;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; RISK; RISK ASSESSMENT; VACCINATION;

EID: 84861483244     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.10.015     Document Type: Review

References (53)

1. Bijl M., Kallenberg C.G., van Assen S. Vaccination of the immune-compromised patients with focus on patients with autoimmune-inflammatory diseases. Neth J Med 2011, 69(1):5-13. Jan;.
2. Agmon-Levin N., Paz Z., Israeli E., et al. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
3. Shoenfeld Y., Agmon-Levin N. 'ASIA' - Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
4. Chevrel G., Zech C., Miossec P. Severe uveitis followed by reactive arthritis after bacillus Calmette-Guerin therapy. J Rheumatol 1999, 26:1011.
5. Devlin M., Deodhar A., Davis M. Arthritis as a complication of intravesical BCG vaccine. BMJ 1994, 308:1638.
6. Dudelzak J., Curtis A.R., Sheehan D.J., et al. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guerin (BCG) immunotherapy. J Drugs Dermatol 2008, 7:684.
7. Durand J.M. Arthritis after intravesicular BCG therapy. Presse Med 1998, 27:918.
8. Faus S., Martinez Montauti J.M., Puig L. Reiter's syndrome after administration of intravesical bacille Calmette-Guerin. Clin Infect Dis 1993, 17:526-527.
9. Hansen C.P., Mortensen S. Epididymo-orchitis and Reiter's disease. Two infrequent complications after intravesical bacillus Calmette-Guerin therapy. Scand J Urol Nephrol 1997, 31:317-318.
10. Antony D., Jessy P.L. Involvement of BCG scar in Kawasaki disease. Indian Pediatr 2005, 42:83-84.
11. Genereau T., Koeger A.C., Chaibi P., et al. Polymyalgia rheumatica with temporal arteritis following intravesical Calmette-Guerin bacillus immunotherapy for bladder cancer. Clin Exp Rheumatol 1996, 14:110.
12. Granel B., Serratrice J., Morange P.E., et al. Cryoglobulinemia vasculitis following intravescical instillations of bacillus Calmette-Guerin. Clin Exp Rheumatol 2004, 22:481-482.
13. Kothari S.S. Aetiopathogenesis of Takayasu's arteritis and BCG vaccination: the missing link? Med. Hypotheses. 1995, 45:227-230.
14. Lubbe D. Vasculitis allergica of papulonecrotic type following BCG vaccination (author's transl). Dermatol Monatsschr 1982, 168:186-192.
15. Misery L., Combemale P. BCG-vaccine-induced lupus vulgaris and urticarial vasculitis. Dermatology 1993, 186:274.
16. Watson D.A. Pustular vasculitis complicating BCG vaccination. Tuber Lung Dis 1992, 73:126.
17. Weinstein M. Inflammation at a previous inoculation site: an unusual presentation of Kawasaki disease. Cmaj. 2006, 174:459-460.
18. Kass E., Straume S., Mellbye O.J., et al. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol 1979, 8:187-191.
19. Kass E., Straume S., Munthe E. Dermatomyositis after B.C.G. vaccination. Lancet 1978, 1:772.
20. Farsinejad K., Daneshpazhooh M., Sairafi H., et al. Lupus vulgaris at the site of BCG vaccination: report of three cases. Clin Exp Dermatol 2009, 34:e167-e169.
21. Fellner M.J., Kantor I., Reiner E. Lupus vulgaris-like reaction following BCG vaccination. J Mt Sinai Hosp NY 1963, 30:161-165.
22. van Assen S., Agmon-Levin N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
23. Gershon A.A., Levin M.J., Weinberg A., et al. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 2009, 28:653-655.
24. Barbosa C.M.P., Terreri M.T., Len C.A., et al. Varicella Vaccine in Children and Adolescents with Systemic Lupus Erythematosus (SLE) - Immunogenicity and Safety 2009, ACR-1521.
25. Pileggi G.S., de Souza C.B.S., Ferriani V.P.L. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases using methotrexate and corticosteroids. Arthritis Rheum 2009, 60:1091.
26. Nussinovitch M., Harel L., Varsano I. Arthritis after mumps and measles vaccination. Arch Dis Child 1995, 72:348-349.
27. Tingle A.J., Allen M., Petty R.E., et al. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation. Ann Rheum Dis 1986, 45:110-114.
28. Geier D.A., Geier M.R. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin Exp Rheumatol 2002, 20:767-771.
29. Pattison E., Harrison B.J., Griffiths C.E., et al. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008, 67:672-676.
30. Maillefert J.F., Sibilia J., Toussirot E., et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) 1999, 38:978-983.
31. Geier D.A., Geier M.R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005, 38:295-301.
32. Sturkenbbom MC F.B., Rozenberg S., Bégaud B., et al. Vaccinations against hepatitis B and lupus erythematosus. Pharmacoepidemiol. Drug Safety. 2000, 9:s71.
33. Elkayam O., Yaron M., Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61:623-625.
34. Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Dev Immunol 2006, 13:349-351.
35. Elkayam O., Ablin J., Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev 2007, 6:312-314.
36. Elkayam O., Paran D., Burke M., et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 2005, 38:493-496.
37. Elkayam O., Paran D., Caspi D., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002, 34:147-153.
38. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998, 158:1769-1776.
39. Hak E., Nordin J., Wei F., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002, 35:370-377.
40. Heijstek M.W., de Bruin LM Ott, Bijl M., et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011, 70:1704-1712.
41. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
42. Cervera R., Khamashta M.A., Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999, 78:167-175.
43. Heijstek M.W., de Bruin LM Ott, Borrow R., et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev 2011, Aug. 28 [Epub ahead of print].
44. Gelinck L.B., Teng Y.K., Rimmelzwaan G.F., et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007, 66:1402-1403.
45. Oren S., Mandelboim M., Braun-Moscovici Y., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008, 67:937-941.
46. van Assen S., Holvast A., Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
47. Bingham C.O., Looney R.J., Deodhar A., et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74.
48. Gabay C., Bel M., Combescure C., et al. H1N1 Study Group: Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011 Jun, 63(6):1486-1496. 10.1002/art. 30325.
49. Kapetanovic M.C., Roseman C., Jönsson G., et al. Methotrexate but not TNF-blockers reduces antibody response following pneumococcal vaccination using 7-valent conjugate pneumococcal vaccine in adult patients with established arthritis. Arthritis Rheum 2011, Aug 10. 10.1002/art.30580.
50. Devilliers H A.M., Krivine A., et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) non-adjuvanted vaccine in Systemic Lupus Erythematosus. Arthritis Rheum 2011, Aug 2., [Epub ahead of print]. 10.1002/art.30576.
51. Prymula R., Siegrist C.A., Chlibek R., et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009, 17;374((9698):1339-1350.
52. Elkayam O., Bashkin A., Mandelboim M., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010, 39(6):442-447.
53. van Assen S., Elkayam O., Agmon-Levin N., et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011, 10:341-352.